resVida and Fat Oxidation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

18 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-10-31

Study Completion Date

2011-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

There is now a general consensus that the combination of excessive energy intake and a low capacity to oxidize fat will lead to muscular fat accumulation and insulin resistance. It is known for many years that physical exercise is the most powerful treatment to combat insulin resistance, but it is also known that it is difficult to get people to exercise. A major breakthrough has come from the nutrition field, with the finding that resveratrol, a natural polyphenolic compound, could serve as an "exercise mimetic" by protecting mice from many detrimental effects of diet-induced obesity. Therefore the researchers would like to investigate if resVida can increase skeletal muscle mitochondrial function and fat oxidative capacity in obese subjects. The researchers hypothesize that an increased mitochondrial function together with an increased intrinsic activity will lead to a better control of fatty acid handling in muscle, upon a high-fat challenge.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of resVida on Liver Fat Content

NCT01635114

Elevated Liver Fat Content and Insulin Resistance

COMPLETED NA

Hepatic Glycogen and Fat Oxidation

NCT03593343

Fatty Liver, Nonalcoholic Meal Time Fasting +1 more

COMPLETED NA

Effect of Nicotinamide Riboside on Ketosis, Fat Oxidation & Metabolic Rate

NCT06044935

Overweight Obesity

RECRUITING NA

Resveratrol for the Treatment of Non Alcoholic Fatty Liver Disease and Insulin Resistance in Overweight Adolescents

NCT02216552

NAFLD TYPE 2 DIABETES METABOLIC SYNDROME

COMPLETED PHASE2/PHASE3

Long-term Resveratrol and Metabolism

NCT02565979

Pre-diabetes

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

placebo

starch pill

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type DIETARY_SUPPLEMENT

resVida or placebo will be given for 30 days, twice daily. One pill, which contains 75 mg of resVida, will be provided with lunch, and the other pill will be provided with diner. So in total, 150 mg/day will be given.

resVida

synthetic pill containing 75 mg of resveratrol

Group Type ACTIVE_COMPARATOR

resVida

Intervention Type DIETARY_SUPPLEMENT

resVida or placebo will be given for 30 days, twice daily. One pill, which contains 75 mg of resVida, will be provided with lunch, and the other pill will be provided with diner. So in total, 150 mg/day will be given.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

resVida

resVida or placebo will be given for 30 days, twice daily. One pill, which contains 75 mg of resVida, will be provided with lunch, and the other pill will be provided with diner. So in total, 150 mg/day will be given.

Intervention Type DIETARY_SUPPLEMENT

placebo

resVida or placebo will be given for 30 days, twice daily. One pill, which contains 75 mg of resVida, will be provided with lunch, and the other pill will be provided with diner. So in total, 150 mg/day will be given.

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

resveratrol

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* male sex
* age 45-65 years
* body fat percentage \> 25%, BMI 30-35 kg/m2
* sedentary
* stable dietary habits
* willingness to abstain from ingestion of resveratrol-containing foods
* healthy

Exclusion Criteria

* female sex
* unstable body weight (weight gain or loss \> 3 kg in the last three months)
* total body fat percentage \< 25%
* fasting plasma glucose \> 6.1 mmol/l
* hemoglobin \< 7.8 mmol/l
* engagement in programmed exercise \> 2 hours total per week
* impaired kidney and/ or liver function
* first- or second-degree family member with type 2 diabetes mellitus
* any medical condition requiring treatment and/ or medication use
* intake of dietary supplements except vitamins and minerals
* unwilling to restrict high-resveratrol containing foods
* current alcohol consumption \> 20 grams/day
* participation in another biomedical study within 1 month before the screening visit
* a contraindication to MRI scanning. These contraindications include patients with the following devices:
* central nervous system aneurysm clips
* implanted neural stimulator
* implanted cardiac pacemaker or defibrillator
* cochlear implant
* insulin pump
* or metal containing corpora aliena in the eye or brains

Minimum Eligible Age

45 Years

Maximum Eligible Age

65 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes